WO2022247972A2 - Uso de composiciones terapéuticas para el tratamiento de pacientes con tumores de origen epitelial - Google Patents
Uso de composiciones terapéuticas para el tratamiento de pacientes con tumores de origen epitelial Download PDFInfo
- Publication number
- WO2022247972A2 WO2022247972A2 PCT/CU2022/050004 CU2022050004W WO2022247972A2 WO 2022247972 A2 WO2022247972 A2 WO 2022247972A2 CU 2022050004 W CU2022050004 W CU 2022050004W WO 2022247972 A2 WO2022247972 A2 WO 2022247972A2
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- kras
- patients
- treatment
- use according
- cancer
- Prior art date
Links
- 206010028980 Neoplasm Diseases 0.000 title claims abstract description 76
- 239000000203 mixture Substances 0.000 title claims abstract description 41
- 238000011282 treatment Methods 0.000 title claims abstract description 38
- 230000001225 therapeutic effect Effects 0.000 title claims abstract description 27
- 101000584612 Homo sapiens GTPase KRas Proteins 0.000 claims abstract description 78
- 102100030708 GTPase KRas Human genes 0.000 claims abstract description 72
- 101800003838 Epidermal growth factor Proteins 0.000 claims abstract description 20
- 229940116977 epidermal growth factor Drugs 0.000 claims abstract description 20
- VBEQCZHXXJYVRD-GACYYNSASA-N uroanthelone Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CS)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CS)C(=O)N[C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)C(C)C)[C@@H](C)O)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CCSC)NC(=O)[C@H](CS)NC(=O)[C@@H](NC(=O)CNC(=O)CNC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CS)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CS)NC(=O)CNC(=O)[C@H]1N(CCC1)C(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC(N)=O)C(C)C)[C@@H](C)CC)C1=CC=C(O)C=C1 VBEQCZHXXJYVRD-GACYYNSASA-N 0.000 claims abstract description 20
- 239000003446 ligand Substances 0.000 claims abstract description 19
- 230000019491 signal transduction Effects 0.000 claims abstract description 14
- 201000011510 cancer Diseases 0.000 claims abstract description 13
- 150000001875 compounds Chemical class 0.000 claims abstract description 8
- 102000049555 human KRAS Human genes 0.000 claims abstract description 5
- 102000009024 Epidermal Growth Factor Human genes 0.000 claims abstract 3
- 229960005486 vaccine Drugs 0.000 claims description 19
- 229960003301 nivolumab Drugs 0.000 claims description 17
- 238000000034 method Methods 0.000 claims description 16
- 108090000623 proteins and genes Proteins 0.000 claims description 11
- 239000002671 adjuvant Substances 0.000 claims description 8
- 208000002154 non-small cell lung carcinoma Diseases 0.000 claims description 8
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 claims description 8
- GVUGOAYIVIDWIO-UFWWTJHBSA-N nepidermin Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)NC(=O)CNC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@H](CS)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CS)NC(=O)[C@H](C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CCSC)NC(=O)[C@H](CS)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CS)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CS)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC(N)=O)C(C)C)[C@@H](C)CC)C(C)C)C(C)C)C1=CC=C(O)C=C1 GVUGOAYIVIDWIO-UFWWTJHBSA-N 0.000 claims description 7
- 102000004169 proteins and genes Human genes 0.000 claims description 7
- 102000014914 Carrier Proteins Human genes 0.000 claims description 6
- 108010078791 Carrier Proteins Proteins 0.000 claims description 6
- 101000851176 Homo sapiens Pro-epidermal growth factor Proteins 0.000 claims description 6
- 238000004519 manufacturing process Methods 0.000 claims description 6
- 229960003852 atezolizumab Drugs 0.000 claims description 4
- 229950009791 durvalumab Drugs 0.000 claims description 4
- 229960002621 pembrolizumab Drugs 0.000 claims description 4
- 210000004881 tumor cell Anatomy 0.000 claims description 4
- YYGNTYWPHWGJRM-UHFFFAOYSA-N (6E,10E,14E,18E)-2,6,10,15,19,23-hexamethyltetracosa-2,6,10,14,18,22-hexaene Chemical compound CC(C)=CCCC(C)=CCCC(C)=CCCC=C(C)CCC=C(C)CCC=C(C)C YYGNTYWPHWGJRM-UHFFFAOYSA-N 0.000 claims description 3
- 108010074708 B7-H1 Antigen Proteins 0.000 claims description 3
- 102000008096 B7-H1 Antigen Human genes 0.000 claims description 3
- 102000009016 Cholera Toxin Human genes 0.000 claims description 3
- 108010049048 Cholera Toxin Proteins 0.000 claims description 3
- 206010009944 Colon cancer Diseases 0.000 claims description 3
- 208000001333 Colorectal Neoplasms Diseases 0.000 claims description 3
- 241001465754 Metazoa Species 0.000 claims description 3
- 241000588650 Neisseria meningitidis Species 0.000 claims description 3
- BHEOSNUKNHRBNM-UHFFFAOYSA-N Tetramethylsqualene Natural products CC(=C)C(C)CCC(=C)C(C)CCC(C)=CCCC=C(C)CCC(C)C(=C)CCC(C)C(C)=C BHEOSNUKNHRBNM-UHFFFAOYSA-N 0.000 claims description 3
- 239000004480 active ingredient Substances 0.000 claims description 3
- 229950002916 avelumab Drugs 0.000 claims description 3
- PRAKJMSDJKAYCZ-UHFFFAOYSA-N dodecahydrosqualene Natural products CC(C)CCCC(C)CCCC(C)CCCCC(C)CCCC(C)CCCC(C)C PRAKJMSDJKAYCZ-UHFFFAOYSA-N 0.000 claims description 3
- 206010073071 hepatocellular carcinoma Diseases 0.000 claims description 3
- 231100000844 hepatocellular carcinoma Toxicity 0.000 claims description 3
- 229910052500 inorganic mineral Inorganic materials 0.000 claims description 3
- 239000002502 liposome Substances 0.000 claims description 3
- 239000011707 mineral Substances 0.000 claims description 3
- 229950010773 pidilizumab Drugs 0.000 claims description 3
- 229940031439 squalene Drugs 0.000 claims description 3
- TUHBEKDERLKLEC-UHFFFAOYSA-N squalene Natural products CC(=CCCC(=CCCC(=CCCC=C(/C)CCC=C(/C)CC=C(C)C)C)C)C TUHBEKDERLKLEC-UHFFFAOYSA-N 0.000 claims description 3
- 208000017572 squamous cell neoplasm Diseases 0.000 claims description 3
- 229960000814 tetanus toxoid Drugs 0.000 claims description 3
- 206010044412 transitional cell carcinoma Diseases 0.000 claims description 3
- 206010006187 Breast cancer Diseases 0.000 claims description 2
- 208000026310 Breast neoplasm Diseases 0.000 claims description 2
- 206010008342 Cervix carcinoma Diseases 0.000 claims description 2
- 206010014733 Endometrial cancer Diseases 0.000 claims description 2
- 206010014759 Endometrial neoplasm Diseases 0.000 claims description 2
- 208000000461 Esophageal Neoplasms Diseases 0.000 claims description 2
- 208000002030 Merkel cell carcinoma Diseases 0.000 claims description 2
- 206010029266 Neuroendocrine carcinoma of the skin Diseases 0.000 claims description 2
- 208000006265 Renal cell carcinoma Diseases 0.000 claims description 2
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 claims description 2
- 229940121420 cemiplimab Drugs 0.000 claims description 2
- 201000010881 cervical cancer Diseases 0.000 claims description 2
- 208000017763 cutaneous neuroendocrine carcinoma Diseases 0.000 claims description 2
- 201000003914 endometrial carcinoma Diseases 0.000 claims description 2
- 208000014829 head and neck neoplasm Diseases 0.000 claims description 2
- 208000026037 malignant tumor of neck Diseases 0.000 claims description 2
- 201000010106 skin squamous cell carcinoma Diseases 0.000 claims description 2
- 206010041823 squamous cell carcinoma Diseases 0.000 claims description 2
- 208000023747 urothelial carcinoma Diseases 0.000 claims description 2
- 235000013311 vegetables Nutrition 0.000 claims description 2
- 206010030155 Oesophageal carcinoma Diseases 0.000 claims 1
- 201000004101 esophageal cancer Diseases 0.000 claims 1
- 230000002496 gastric effect Effects 0.000 claims 1
- 230000004083 survival effect Effects 0.000 abstract description 15
- 229940079593 drug Drugs 0.000 abstract description 3
- 239000003814 drug Substances 0.000 abstract description 3
- 101001117317 Homo sapiens Programmed cell death 1 ligand 1 Proteins 0.000 description 22
- 102100024216 Programmed cell death 1 ligand 1 Human genes 0.000 description 22
- 102100040678 Programmed cell death protein 1 Human genes 0.000 description 21
- 102400001368 Epidermal growth factor Human genes 0.000 description 17
- 230000035772 mutation Effects 0.000 description 15
- 230000008901 benefit Effects 0.000 description 13
- 102000001301 EGF receptor Human genes 0.000 description 12
- 108060006698 EGF receptor Proteins 0.000 description 12
- 210000002966 serum Anatomy 0.000 description 10
- 230000004044 response Effects 0.000 description 9
- 238000002560 therapeutic procedure Methods 0.000 description 9
- 206010069755 K-ras gene mutation Diseases 0.000 description 8
- 230000011664 signaling Effects 0.000 description 6
- 102000001708 Protein Isoforms Human genes 0.000 description 5
- 108010029485 Protein Isoforms Proteins 0.000 description 5
- 230000000903 blocking effect Effects 0.000 description 5
- 238000013517 stratification Methods 0.000 description 5
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 4
- 201000010099 disease Diseases 0.000 description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 4
- 239000003112 inhibitor Substances 0.000 description 4
- 230000002401 inhibitory effect Effects 0.000 description 4
- 230000003993 interaction Effects 0.000 description 4
- 201000005202 lung cancer Diseases 0.000 description 4
- 208000020816 lung neoplasm Diseases 0.000 description 4
- 101150105104 Kras gene Proteins 0.000 description 3
- 210000004027 cell Anatomy 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- 210000004072 lung Anatomy 0.000 description 3
- 230000006641 stabilisation Effects 0.000 description 3
- 238000011105 stabilization Methods 0.000 description 3
- 208000010507 Adenocarcinoma of Lung Diseases 0.000 description 2
- 229940076838 Immune checkpoint inhibitor Drugs 0.000 description 2
- 238000012369 In process control Methods 0.000 description 2
- 208000005718 Stomach Neoplasms Diseases 0.000 description 2
- 208000009956 adenocarcinoma Diseases 0.000 description 2
- 150000001413 amino acids Chemical group 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 230000006023 anti-tumor response Effects 0.000 description 2
- 238000003556 assay Methods 0.000 description 2
- 229960005395 cetuximab Drugs 0.000 description 2
- 210000001072 colon Anatomy 0.000 description 2
- 208000029742 colonic neoplasm Diseases 0.000 description 2
- 238000002648 combination therapy Methods 0.000 description 2
- 230000001186 cumulative effect Effects 0.000 description 2
- 210000004544 dc2 Anatomy 0.000 description 2
- 230000007120 differential activation Effects 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 206010017758 gastric cancer Diseases 0.000 description 2
- 210000000987 immune system Anatomy 0.000 description 2
- 239000012274 immune-checkpoint protein inhibitor Substances 0.000 description 2
- 230000002163 immunogen Effects 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- 238000004190 ion pair chromatography Methods 0.000 description 2
- 238000012423 maintenance Methods 0.000 description 2
- 230000037361 pathway Effects 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 238000012163 sequencing technique Methods 0.000 description 2
- 238000009097 single-agent therapy Methods 0.000 description 2
- 201000011549 stomach cancer Diseases 0.000 description 2
- 206010052747 Adenocarcinoma pancreas Diseases 0.000 description 1
- 206010067484 Adverse reaction Diseases 0.000 description 1
- 102000007299 Amphiregulin Human genes 0.000 description 1
- 108010033760 Amphiregulin Proteins 0.000 description 1
- JEDPSOYOYVELLZ-UHFFFAOYSA-N COc1nc(OCc2cccc(c2C)-c2ccccc2)ccc1CNCCNC(C)=O Chemical compound COc1nc(OCc2cccc(c2C)-c2ccccc2)ccc1CNCCNC(C)=O JEDPSOYOYVELLZ-UHFFFAOYSA-N 0.000 description 1
- HFOBENSCBRZVSP-LKXGYXEUSA-N C[C@@H](O)[C@H](NC(=O)N[C@@H](CC(N)=O)c1nc(no1)[C@@H](N)CO)C(O)=O Chemical compound C[C@@H](O)[C@H](NC(=O)N[C@@H](CC(N)=O)c1nc(no1)[C@@H](N)CO)C(O)=O HFOBENSCBRZVSP-LKXGYXEUSA-N 0.000 description 1
- 208000005623 Carcinogenesis Diseases 0.000 description 1
- 208000017897 Carcinoma of esophagus Diseases 0.000 description 1
- 208000005443 Circulating Neoplastic Cells Diseases 0.000 description 1
- QBXVXKRWOVBUDB-GRKNLSHJSA-N ClC=1C(=CC(=C(CN2[C@H](C[C@H](C2)O)C(=O)O)C1)OCC1=CC(=CC=C1)C#N)OCC1=C(C(=CC=C1)C1=CC2=C(OCCO2)C=C1)C Chemical compound ClC=1C(=CC(=C(CN2[C@H](C[C@H](C2)O)C(=O)O)C1)OCC1=CC(=CC=C1)C#N)OCC1=C(C(=CC=C1)C1=CC2=C(OCCO2)C=C1)C QBXVXKRWOVBUDB-GRKNLSHJSA-N 0.000 description 1
- 238000001712 DNA sequencing Methods 0.000 description 1
- 238000009007 Diagnostic Kit Methods 0.000 description 1
- 238000002965 ELISA Methods 0.000 description 1
- 238000008157 ELISA kit Methods 0.000 description 1
- 101500025419 Homo sapiens Epidermal growth factor Proteins 0.000 description 1
- 101000628562 Homo sapiens Serine/threonine-protein kinase STK11 Proteins 0.000 description 1
- 102000037984 Inhibitory immune checkpoint proteins Human genes 0.000 description 1
- 108091008026 Inhibitory immune checkpoint proteins Proteins 0.000 description 1
- 108091028043 Nucleic acid sequence Proteins 0.000 description 1
- 108700020796 Oncogene Proteins 0.000 description 1
- 206010061902 Pancreatic neoplasm Diseases 0.000 description 1
- 101710089372 Programmed cell death protein 1 Proteins 0.000 description 1
- 102100026715 Serine/threonine-protein kinase STK11 Human genes 0.000 description 1
- 101150080074 TP53 gene Proteins 0.000 description 1
- 230000001594 aberrant effect Effects 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 230000006838 adverse reaction Effects 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 230000005540 biological transmission Effects 0.000 description 1
- 210000000481 breast Anatomy 0.000 description 1
- 230000036952 cancer formation Effects 0.000 description 1
- 231100000504 carcinogenesis Toxicity 0.000 description 1
- 210000000038 chest Anatomy 0.000 description 1
- 230000006552 constitutive activation Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 210000000981 epithelium Anatomy 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 231100000171 higher toxicity Toxicity 0.000 description 1
- 229940116978 human epidermal growth factor Drugs 0.000 description 1
- 210000002865 immune cell Anatomy 0.000 description 1
- 230000002055 immunohistochemical effect Effects 0.000 description 1
- 230000001024 immunotherapeutic effect Effects 0.000 description 1
- 238000009169 immunotherapy Methods 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 208000037841 lung tumor Diseases 0.000 description 1
- 230000036210 malignancy Effects 0.000 description 1
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 201000001441 melanoma Diseases 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 102000006240 membrane receptors Human genes 0.000 description 1
- 108020004084 membrane receptors Proteins 0.000 description 1
- 230000001394 metastastic effect Effects 0.000 description 1
- 206010061289 metastatic neoplasm Diseases 0.000 description 1
- 238000002493 microarray Methods 0.000 description 1
- 229960000513 necitumumab Drugs 0.000 description 1
- 229950010203 nimotuzumab Drugs 0.000 description 1
- 150000007523 nucleic acids Chemical group 0.000 description 1
- 108700025694 p53 Genes Proteins 0.000 description 1
- 210000000496 pancreas Anatomy 0.000 description 1
- 201000002094 pancreatic adenocarcinoma Diseases 0.000 description 1
- 201000002528 pancreatic cancer Diseases 0.000 description 1
- 208000008443 pancreatic carcinoma Diseases 0.000 description 1
- 229960001972 panitumumab Drugs 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 238000003752 polymerase chain reaction Methods 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 208000037821 progressive disease Diseases 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 102000027426 receptor tyrosine kinases Human genes 0.000 description 1
- 108091008598 receptor tyrosine kinases Proteins 0.000 description 1
- 102000005962 receptors Human genes 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- 230000000306 recurrent effect Effects 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 238000002626 targeted therapy Methods 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 210000000115 thoracic cavity Anatomy 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 230000004614 tumor growth Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/00113—Growth factors
- A61K39/001131—Epidermal growth factor [EGF]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001102—Receptors, cell surface antigens or cell surface determinants
- A61K39/001103—Receptors for growth factors
- A61K39/001104—Epidermal growth factor receptors [EGFR]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39541—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against normal tissues, cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2827—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
- C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55516—Proteins; Peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55588—Adjuvants of undefined constitution
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
- A61K2039/575—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 humoral response
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/58—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation
- A61K2039/585—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation wherein the target is cancer
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
- A61K2039/6031—Proteins
- A61K2039/6037—Bacterial toxins, e.g. diphteria toxoid [DT], tetanus toxoid [TT]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
- A61K2039/6031—Proteins
- A61K2039/6068—Other bacterial proteins, e.g. OMP
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
- A61K2039/6031—Proteins
- A61K2039/6081—Albumin; Keyhole limpet haemocyanin [KLH]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/156—Polymorphic or mutational markers
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
Definitions
- the present invention relates to the branches of Biotechnology and Medicine.
- the use of therapeutic compositions for the treatment of patients with tumors of epithelial origin by means of the simultaneous blockade of the epidermal growth factor and the PD1/PD1 ligand signaling pathway is described.
- checkpoints The antitumor response generated by the immune system is negatively regulated by molecules called "checkpoints", among which the PD1 receptor and its PDL1 ligand stand out.
- Monoclonal antibodies (mAbs) that block the transmission of the inhibitory signal at these checkpoints induce a more effective antitumor response.
- mAbs Monoclonal antibodies that block the transmission of the inhibitory signal at these checkpoints
- anti-CPI for its acronym in English: immune checkpoint inhibitors
- seven checkpoint inhibitor mAbs have been approved for the treatment of numerous “immunosensitive” malignancies, such as melanoma, lung cancer, head and neck squamous cell tumors, hepatocellular carcinoma, urothelial cancer, gastric cancer, cancer breast and colorectal tumors (Ravindranathan D et al.
- the epidermal growth factor receptor (EGFR) is a receptor tyrosine kinase and known oncogene (Yarden Y. (2001) European Journal of Cancer. 37:S3-S8), which is activated by seven natural ligands.
- EGFR epidermal growth factor receptor
- Ligands such as EGF induce signaling that favors tumor proliferation while low affinity ligands such as amphiregulin promote differentiation (Freed DM et al. (2017) Cell 171: 1-13).
- a therapeutic modality that targets EGFR ligands is the use of vaccine compositions that induce specific antibodies (Abs) against a ligand, blocking its interaction with EGFR.
- An example of this therapeutic strategy is the CIMAvax-EGF vaccine that generates specific Abs against the human epidermal growth factor (EGF), depriving the tumor of this important ligand.
- NSCLC non-small cell lung cancer
- KRAS GTPase One of the most important molecules involved in signaling through EGFR is the KRAS GTPase. This molecule activates, in turn, multiple signaling cascades involved in tumorigenesis. Approximately 30% of all human tumors have mutations in the gene encoding KRAS, which induces some constitutive activation of the EGF-R cascade independently of conventional membrane receptor activation (Fernández-Medarde, A y cols. (2011) Genes and Cancer. 2: 344-358). In some of these neoplasms, the mutation in this gene predominates, as is the case of pancreatic adenocarcinoma, present in 90% of tumors. In other adenocarcinomas such as colon cancer, it is present in 40% of them.
- the KRAS mutation is present in 30% of all non-small cell lung tumors, mainly in adenocarcinoma histology (Moore AR et al. (2020) Nat Rev Drug Discov. 19(8 ): 533-552).
- the mutation or not of KRAS in tumors does not influence or condition, by itself, the clinical response of patients to anti-PD1/PDL1 mAbs.
- significant clinical benefit was observed for patients with KRAS mutated tumors (Borghaei, H et al. (2015) N Engl J Med. 373(17): 1627-1639; Socinski May cols. (2016) N Engl J Med. 378(24):2288-2301).
- recent clinical trials show that the presence of other mutations together with mutations in KRAS (co-mutations) could condition a better or worse response in patients treated with anti-PD1/PDL1 mAbs.
- This invention reports, for the first time, the use of a therapeutic composition that combines Abs that block the interaction between PD1 and PDL1 and a vaccine composition that induces Abs against autologous human EGF, in patients with native KRAS.
- the results obtained demonstrate that the therapy is well tolerated and specifically benefits patients with tumors presenting native KRAS. Even more, This therapy benefits patients with tumors with low expression of PD-L1 , who are not very sensitive to therapies with anti-PD1/PDL1 mAbs.
- the present invention relates to the use of therapeutic compositions for the treatment of tumors of epithelial origin.
- Said compositions are characterized in that they comprise a vaccine composition that induces the production of specific Abs against EGF and a compound that blocks the PD1/PD1 ligand signaling pathway.
- the use of the aforementioned therapeutic compositions in those tumors of epithelial origin that express the native form of the KRAS protein is described, preferably those with the sequences described in SEQ ID NO.: 1 and SEQ ID NO.: 2.
- the vaccine compositions that induce the production of Abs against EGF comprise as active ingredient a conjugate between recombinant human EGF and a carrier protein.
- Said carrier protein is selected from the group comprising: cholera toxin B, tetanus toxoid, KLH and p64k from Neisseria meningitidis.
- the vaccine compositions that induce the production of Abs against EGF have an adjuvant that is selected from the group that includes: Freund's incomplete adjuvant, based on squalene, of synthetic origin, of mineral origin, of plant origin, of animal origin , particulate proteins and liposomes.
- the compound that blocks the PD1/PD1 ligand signaling pathway is selected from the group comprising an anti-PD1 Ab, among which are nivolumab, pembrolizumab, MEDI0608 and pidilizumab and an anti-PDL1 Ab, which can be: atezolizumab, durvalumab, avelumab, and MDX-1105.
- patients are selected by determining the presence or absence of native KRAS in a sample of their tumor cells. Those with the presence of native KRAS are selected for treatment. Among the types of tumors that are treated are: lung, colon...
- the present invention relates to a method for stratifying patients into responders or non-responders to treatment with the therapeutic compositions described herein wherein patients are stratified by determining the presence or absence of native KRAS in a sample of tumor cells from the patient and those in whom the presence of native KRAS is detected will be considered treatment responders. Preferably, it Patients whose tumor samples have PDL1 levels below 1% will be considered responders.
- the uses and methods of the present invention are intended for the treatment and/or stratification of patients whose epithelial tumors express the native human KRAS protein.
- the term "native” refers to naturally occurring human KRAS isoforms (Uniprot Accession No. P01116, version 246 of April 7, 2021).
- Native KRAS isoforms are envisioned to be those comprising the sequences SEQ ID NO.: 1 or SEQ ID No. 2.
- native KRAS isoforms may consist of the sequences SEQ ID NO.: 1 or to SEQ ID No. 2.
- KRAS generally also encompasses KRAS polypeptides having mutations relative to the reference sequence shown in SEQ ID NO: 1 (KRAS4A) or SEQ ID No. 2 (KRAS4B) and further encompasses polypeptides which share a certain degree of identity with the amino acid sequences shown in SEQ ID NO: 1 (KRAS4A, Uniprot Accession No. P01116-1) or SEQ ID No. 2 (KRAS4B, Uniprot Accession No. P01116-2) as here it is described.
- native KRAS includes KRAS polypeptides having at least 80%, 85%, 90%, 95%, or 100% identity with SEQ ID NO.: 1 (KRAS4A) or SEQ ID No. 2 (KRAS4B).
- isoforms 4A and 4B are encompassed by the term "native human KRAS”.
- “native KRAS” does not comprise a mutation in its amino acid sequence compared to SEQ ID No. 1 or SEQ ID No. 2 respectively.
- native KRAS and wild type KRAS are used interchangeably herein and refer to the naturally occurring KRAS isoforms described herein.
- the present invention relates to therapeutic compositions for the treatment of cancer particularly directed at blocking the EGF target and the PD1/PD1 ligand signaling pathway.
- the present invention describes the effective use of the combination of compounds against PD1 or its ligand PDL1, with agents that reduce EGF concentrations; in a subpopulation of patients with tumors of epithelial origin, especially those tumors that typically respond to immunotherapy.
- the anti-PD1 mAbs used in the present invention are all those that specifically bind to the PD1 cell surface receptor and block the PD1/PDL1 inhibitory pathway.
- anti-PD1 mAbs are: nivolumab described in US patent 8,008,449), pembrolizumab described in US patents 8,354,509 and US 8,900,587, MEDI0608 (US 8,609,089), pidilizumab (US 8,686,119) and cemiplimab.
- the anti-PDL1 mAbs used in the present invention are all those that specifically bind to PDL1 and block the PD1/PDL1 inhibitory pathway.
- said anti-PDL1 MAbs are: atezolizumab described in US patent 8,217,149, durvalumab (US 8,779,108), avelumab described in US patent 9,624,298 and MDX-1105 (US 7943743).
- low molecular weight inhibitors that suppress the PD1/PDL1 interaction can be combined with agents that reduce EGF concentrations, according to the present invention.
- Such inhibitors include: BMS1166, BMS202 and CA-170.
- the agents that reduce EGF concentrations provided in the present invention are all those vaccine compositions that induce the production of specific Abs against autologous human EGF that block the interaction with the EGF receptor, which contribute to decrease and/or eliminate the serum EGF levels.
- said vaccine compositions are all those that comprise as active principle a conjugate between recombinant human EGF (rhEGF) and a carrier protein.
- Said carrier protein can be: cholera toxin B, tetanus toxoid, KLFI and P64k from Neisseria meningitidis, without being restricted to these.
- said vaccine compositions possess an adjuvant selected from the following: Freund's incomplete adjuvant, squalene-based adjuvants, of synthetic origin, of mineral origin, of vegetable origin, of animal origin, particulate protein adjuvants, and liposomes.
- a tumor sample is usually obtained from the patient to be evaluated, and the KRAS nucleic acid sequence is respectively obtained, amplified from the sample, and undergo sequencing.
- polymerase chain reaction can be used to detect the presence of mutations in the KRAS gene.
- Another method is related to plasma or serum samples in which circulating tumor cells with KRAS oncogene can be detected using membrane microarrays.
- a positive KRAS mutation in plasma or serum suggests a KRAS mutation in the tumor, while the absence of a KRAS mutation in plasma or serum does not necessarily prove the absence of a similar mutation in tumor epithelial tissue.
- wild-type KRAS expression can be determined by detecting wild-type and/or mutated KRAS polypeptides in the tumor sample; for example, by using specific Abs that bind to specific epitopes for wild-type or mutant KRAS, respectively.
- Patients with tumors of epithelial origin expressing wild-type KRAS are expected to be selected for treatment, while patients expressing mutant KRAS are not selected for treatment.
- the present invention also provides a method for the stratification of patients with epithelial tumors.
- "Stratification" when used herein, means classifying patients with epithelial tumors into those who may benefit from treatment with the therapeutic compositions of the present application and those who may not. Patients whose epithelial tumors do not express wild-type KRAS, and in particular patients whose epithelial tumors express mutated KRAS, are unlikely to benefit (respond) to treatment with the therapeutic compositions described herein.
- Said native KRAS preferably has a sequence corresponding to SEQ ID No. 1 or SEQ ID No. 2.
- a patient in the context of the treatment method provided in this application means that a patient, or a tumor, shows a complete response or a partial response or a stabilization of the disease, after administering the therapeutic compositions described herein. invention; according to the Response Criteria for Use in Clinical Trials Testing Immunotherapeutics (iRECIST).
- iRECIST Clinical Trials Testing Immunotherapeutics
- non-responder refers to those patients who show progressive disease after the administration of said therapeutic compositions. iRECIST is described in: Seymour L et al. RECIST working group (2017) Lancet Oncol. 18(3):e143-e152.
- Also provided in the present invention is a method for selecting a patient or patient population to be treated. This is accomplished by determining the presence or absence of mutated and/or wild-type KRAS in a sample of the epithelial tumor from each patient. Patients whose tumor samples have mutated KRAS and/or wild-type KRAS not detected are not considered eligible for treatment, whereas patients whose tumor samples have wild-type KRAS and/or no wild-type KRAS have been detected. KRAS mutants are considered eligible, therefore they are selected for treatment according to the invention.
- the invention allows to provide a method for prognosticating whether or not a patient suffering from cancer of epithelial origin will respond to treatment with the therapeutic compositions described in the present invention.
- the absence or presence of mutated and/or wild-type KRAS in a patient's tumor sample can be assessed using methods known in the art.
- Expression of mutated KRAS in the epithelial tumor indicates that the patient or epithelial tumor will not respond to treatment, whereas expression of wild-type KRAS in the epithelial tumor indicates that the patient has a high probability of responding to treatment with the therapeutic compositions described in the present invention.
- the patients who respond to treatment will be those who express native KRAS and in turn PDL1 levels below 1% measured by immunohistochemical techniques in tumor samples.
- cancers that can be treated with the therapeutic composition described in the present invention are, but are not limited to: NSCLC, squamous cell cancer of the head and neck, urothelial carcinoma, colorectal cancer, gastric cancer, cancer of the esophagus, cervical cancer, hepatocellular carcinoma, Merkel cell carcinoma, renal cell carcinoma, endometrial carcinoma, breast cancer, squamous cell carcinoma of the skin.
- the invention includes refractory or recurrent neoplasms the growth of which can be inhibited using the combination of the invention.
- the administration of the vaccine compositions that include EGF as the active ingredient will preferably be carried out intramuscularly, the first 4 doses every 14 days and the rest, every 28 days, with a permissible time range of 3 days.
- the range of doses in which these compositions will be used will comprise between 20-70 pL/kg of weight or 20-70 pg of total proteins per kilogram of weight or up to 5 mg of total proteins, with 30-60 pg/kg being more recommended.
- the treatment stage will have a minimum duration of 6 months, followed by a maintenance stage that can vary in frequency and dose according to the results obtained and can be Optimize taking into account the A titer generated and the improvement and/or stabilization of clinical symptoms, provided that a reduction in serum EGF concentrations is guaranteed.
- Said serum EGF concentrations can be measured by any of the commercially available diagnostic kits for this purpose.
- the anti-PD1 and anti-PDL1 mAbs will be administered in the doses and schedules recommended for each case.
- 100-500 mg of total protein will be administered intravenously in a dose range between two to six weeks.
- the anti-PDL1 will be administered intravenously in a range between 600-1800 mg of total proteins with a frequency of between two to five weeks.
- the administration of the vaccine and the mAbs will be adjusted so that the action of blocking PD1/PD1 L signaling and the inhibition of EGF-mediated signaling coincide. Following this principle, the administration can be concomitant or sequential. In particular, the administration of the vaccine composition can overlap with the administration schedules of the Abs.
- Figure 3 Cumulative survival of patients treated with CIMAvax-EGF and nivolumab over time, in patients with KRAS wild-type and KRAS-mutated tumors.
- Figure 4 Cumulative survival of patients treated with CIMAvax-EGF and nivolumab over time, for patients with ⁇ 1% PD-L1 tumors, that are KRAS wild type or KRAS mutated.
- Example 1 The combined administration of CIMAvax-EGF and the anti-PD1 mAb nivolumab is safe and induces a potent human anti-EGF Abs response.
- a therapeutic composition was used that comprises the CIMAvax-EGF vaccine composition, with the ani-PD1 mAb nivolumab, for the treatment of advanced NSCLC patients.
- This study had a Phase I dose escalation and a Phase II efficacy evaluation.
- 29 patients with metastatic NSCLC were included.
- Nivolumab was used at a dose of 240 mg every 2 weeks, intravenously.
- the CIMAvax-EGF vaccine composition was used at a dose of 2.4 mg intramuscularly every 2 weeks during the induction phase (4 doses), followed by monthly injections in the maintenance phase.
- CIMAvax-EGF induced a good response in all patients, defined by an anti-EGF Abs titer equal to or greater than 1:4000 (serum dilution ( Figure 1).
- the median overall survival for the 29 treated patients was 10.36 months.
- the overall survival rate at one year was 44%.
- Example 2 The combined administration of CIMAvax-EGF and the anti ⁇ PD1 AbMant nivolumab significantly benefits patients with native KRAS.
- patients with native KRAS tumors had a significant improvement in disease control rate (patients with at least disease stabilization according to irRECIST criteria (Seymour L et al. RECIST working group (2017) Lancet Oncol. 18 (3):e143-e152), after combination therapy.
- the disease control rate after the combination of CIMAvax-EGF and nivolumab was 56.3% compared with 12.5% in patients with tumors that contain KRAS mutations.
- the survival observed with combination therapy in patients with native KRAS is clinically relevant, since according to the literature, stratification according to KRAS mutations does not influence the survival of patients treated only with nivolumab mAb.
- nivolumab monotherapy resulted in a median survival of 11.2 months and 10 months, in patients with KRAS mutated or wild-type, respectively (Passiglia F et al. (2019) Br J Cancer 120(1 ): 57-62).
- Example 3 The combined administration of CIMAvax-EGF and the anti ⁇ PD1 Ab nivolumab significantly benefits patients with native KRAS tumors and PDL1 ⁇ 1%.
- Example 2 Given the known history in the literature of lower response to anti-PD1 mAb monotherapy in patients with low expression of PDL1 in the tumor, the analysis of Example 2 was repeated for patients whose tumors did not express PDL1 (PDL1 ⁇ 1%). . PDL1 expression was determined using the pharmDx 28-8 assay for PDL1 determination.
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Microbiology (AREA)
- Genetics & Genomics (AREA)
- Mycology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Oncology (AREA)
- Dermatology (AREA)
- Analytical Chemistry (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Pathology (AREA)
- Cell Biology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biotechnology (AREA)
- Physics & Mathematics (AREA)
- Hospice & Palliative Care (AREA)
- Biomedical Technology (AREA)
- General Engineering & Computer Science (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Steroid Compounds (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Abstract
Description
Claims
Priority Applications (8)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
BR112023024775A BR112023024775A2 (pt) | 2021-05-26 | 2022-05-19 | Uso de uma composição terapêutica, e, método de estratificação de pacientes |
KR1020237042874A KR20240014054A (ko) | 2021-05-26 | 2022-05-19 | 상피 유래 종양을 가진 환자를 치료하기 위한 치료용 조성물의 용도 |
US17/789,888 US20240173392A1 (en) | 2021-05-26 | 2022-05-19 | Use of therapeutic compositions for the treatment of patients with tumors of epithelial origin |
JP2023573145A JP2024520067A (ja) | 2021-05-26 | 2022-05-19 | 上皮起源の腫瘍を有する患者の処置のための治療用組成物の使用 |
CA3220191A CA3220191A1 (en) | 2021-05-26 | 2022-05-19 | Use of therapeutic compositions for the treatment of patients with tumours of epithelial origin |
CN202280037573.4A CN117396512A (zh) | 2021-05-26 | 2022-05-19 | 治疗组合物用于治疗上皮源性肿瘤患者的用途 |
AU2022280921A AU2022280921A1 (en) | 2021-05-26 | 2022-05-19 | Use of therapeutic compositions for the treatment of patients with tumours of epithelial origin |
EP22735763.9A EP4349863A2 (en) | 2021-05-26 | 2022-05-19 | Use of therapeutic compositions for the treatment of patients with tumours of epithelial origin |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CU2021-0045 | 2021-05-26 | ||
CU20210045 | 2021-05-26 |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2022247972A2 true WO2022247972A2 (es) | 2022-12-01 |
WO2022247972A3 WO2022247972A3 (es) | 2023-01-12 |
Family
ID=82358374
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/CU2022/050004 WO2022247972A2 (es) | 2021-05-26 | 2022-05-19 | Uso de composiciones terapéuticas para el tratamiento de pacientes con tumores de origen epitelial |
Country Status (10)
Country | Link |
---|---|
US (1) | US20240173392A1 (es) |
EP (1) | EP4349863A2 (es) |
JP (1) | JP2024520067A (es) |
KR (1) | KR20240014054A (es) |
CN (1) | CN117396512A (es) |
AU (1) | AU2022280921A1 (es) |
BR (1) | BR112023024775A2 (es) |
CA (1) | CA3220191A1 (es) |
TW (1) | TW202313106A (es) |
WO (1) | WO2022247972A2 (es) |
Citations (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7943743B2 (en) | 2005-07-01 | 2011-05-17 | Medarex, Inc. | Human monoclonal antibodies to programmed death ligand 1 (PD-L1) |
US8008449B2 (en) | 2005-05-09 | 2011-08-30 | Medarex, Inc. | Human monoclonal antibodies to programmed death 1 (PD-1) and methods for treating cancer using anti-PD-1 antibodies alone or in combination with other immunotherapeutics |
US8217149B2 (en) | 2008-12-09 | 2012-07-10 | Genentech, Inc. | Anti-PD-L1 antibodies, compositions and articles of manufacture |
US8354509B2 (en) | 2007-06-18 | 2013-01-15 | Msd Oss B.V. | Antibodies to human programmed death receptor PD-1 |
US8609089B2 (en) | 2008-08-25 | 2013-12-17 | Amplimmune, Inc. | Compositions of PD-1 antagonists and methods of use |
US8686119B2 (en) | 2011-07-24 | 2014-04-01 | Curetech Ltd. | Variants of humanized immunomodulatory monoclonal antibodies |
US8779108B2 (en) | 2009-11-24 | 2014-07-15 | Medimmune, Limited | Targeted binding agents against B7-H1 |
US9624298B2 (en) | 2011-11-28 | 2017-04-18 | Merck Patent Gmbh | Anti-PD-L1 antibodies and uses thereof |
-
2022
- 2022-05-19 WO PCT/CU2022/050004 patent/WO2022247972A2/es active Application Filing
- 2022-05-19 EP EP22735763.9A patent/EP4349863A2/en active Pending
- 2022-05-19 JP JP2023573145A patent/JP2024520067A/ja active Pending
- 2022-05-19 BR BR112023024775A patent/BR112023024775A2/pt unknown
- 2022-05-19 US US17/789,888 patent/US20240173392A1/en active Pending
- 2022-05-19 AU AU2022280921A patent/AU2022280921A1/en active Pending
- 2022-05-19 KR KR1020237042874A patent/KR20240014054A/ko unknown
- 2022-05-19 CA CA3220191A patent/CA3220191A1/en active Pending
- 2022-05-19 CN CN202280037573.4A patent/CN117396512A/zh active Pending
- 2022-05-24 TW TW111119253A patent/TW202313106A/zh unknown
Patent Citations (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8008449B2 (en) | 2005-05-09 | 2011-08-30 | Medarex, Inc. | Human monoclonal antibodies to programmed death 1 (PD-1) and methods for treating cancer using anti-PD-1 antibodies alone or in combination with other immunotherapeutics |
US7943743B2 (en) | 2005-07-01 | 2011-05-17 | Medarex, Inc. | Human monoclonal antibodies to programmed death ligand 1 (PD-L1) |
US8354509B2 (en) | 2007-06-18 | 2013-01-15 | Msd Oss B.V. | Antibodies to human programmed death receptor PD-1 |
US8900587B2 (en) | 2007-06-18 | 2014-12-02 | Merck Sharp & Dohme Corp. | Antibodies to human programmed death receptor PD-1 |
US8609089B2 (en) | 2008-08-25 | 2013-12-17 | Amplimmune, Inc. | Compositions of PD-1 antagonists and methods of use |
US8217149B2 (en) | 2008-12-09 | 2012-07-10 | Genentech, Inc. | Anti-PD-L1 antibodies, compositions and articles of manufacture |
US8779108B2 (en) | 2009-11-24 | 2014-07-15 | Medimmune, Limited | Targeted binding agents against B7-H1 |
US8686119B2 (en) | 2011-07-24 | 2014-04-01 | Curetech Ltd. | Variants of humanized immunomodulatory monoclonal antibodies |
US9624298B2 (en) | 2011-11-28 | 2017-04-18 | Merck Patent Gmbh | Anti-PD-L1 antibodies and uses thereof |
Non-Patent Citations (19)
Title |
---|
"Uniprot", Database accession no. P01116-2 |
BESSE B, LUNG CANCER, vol. 142, 2020, pages 63 - 69 |
BORGHAEI, H, N ENGL J MED, vol. 373, no. 17, 2015, pages 1627 - 1639 |
BOURNET B, CLIN TRANSI GASTROENTEROL, vol. 7, 2016, pages e157 |
DONG ZY, CLIN CANCER RES, vol. 23, 2017, pages 3012 - 3024 |
FERNÁNDEZ-MEDARDE, A, GENES AND CANCER, vol. 2, 2011, pages 344 - 358 |
FREED DM, CELL, vol. 171, 2017, pages 1 - 13 |
HAIGIS KM, NAT GENET, vol. 40, 2008, pages 600 - 8 |
MOORE AR, NAT REV DRUG DISCOV, vol. 19, no. 8, 2020, pages 533 - 552 |
PASSIGLIA F, BR J CANCER, vol. 120, no. 1, 2019, pages 57 - 62 |
RODRIGUEZ PC, CLIN CANCER RES, vol. 22, no. 15, 2016, pages 3782 - 90 |
SCHOENFELD AJ, ANN ONCOL., vol. 30, no. 5, 2019, pages 839 - 44 |
SCHULTHEIS B, ANN. ONCOL, vol. 28, 2017, pages 2429 - 35 |
SHEPHERD FA, J CLIN. ONCOL., vol. 31, no. 17, 2013, pages 2173 - 81 |
SKOULIDIS FY, CANCER DISCOV, vol. 8, 2018, pages 822 - 835 |
SOCINSKI MAY, N ENGL J MED, vol. 378, no. 24, 2018, pages 2288 - 2301 |
YANG JC, J THORAC ONCOL., vol. 14, no. 3, 2019, pages 553 - 9 |
YARDEN Y, EUROPEAN JOURNAL OF CANCER, vol. 37, 2001, pages S3 - S8 |
ZER A, J THORACIC. ONCOL., vol. 11, no. 13, 2016, pages 312 - 23 |
Also Published As
Publication number | Publication date |
---|---|
BR112023024775A2 (pt) | 2024-02-15 |
CA3220191A1 (en) | 2022-12-01 |
TW202313106A (zh) | 2023-04-01 |
US20240173392A1 (en) | 2024-05-30 |
CN117396512A (zh) | 2024-01-12 |
JP2024520067A (ja) | 2024-05-21 |
KR20240014054A (ko) | 2024-01-31 |
EP4349863A2 (en) | 2024-04-10 |
WO2022247972A3 (es) | 2023-01-12 |
AU2022280921A1 (en) | 2023-12-07 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ES2364495T3 (es) | Método para tratar cáncer resistente a gefitinib. | |
Quintanal-Villalonga et al. | FGFR1 cooperates with EGFR in lung cancer oncogenesis, and their combined inhibition shows improved efficacy | |
ES2611337T3 (es) | Uso de anticuerpo anti-VEGF en combinación con quimioterapia para tratar cáncer de mama | |
EP3140320B1 (en) | Peptide vaccine comprising mutant ras peptide and chemotherapeutic agent | |
Angevin et al. | A first-in-human phase I study of SAR125844, a selective MET tyrosine kinase inhibitor, in patients with advanced solid tumours with MET amplification | |
EA022743B1 (ru) | Композиция опухолеассоциированных пептидов и относящаяся к ним противораковая вакцина для лечения рака желудка и других видов рака | |
KR20210041571A (ko) | 역형성 림프종 키나아제 억제제와 조합하여 egf/egfr 경로를 억제하기 위한 방법 및 조성물 | |
US20200347140A1 (en) | Compositions and methods for treating cancer with anti-egfr antibodies | |
Camidge et al. | A randomized, open-label phase II study evaluating emibetuzumab plus erlotinib and emibetuzumab monotherapy in MET immunohistochemistry positive NSCLC patients with acquired resistance to erlotinib | |
EP3641818A1 (en) | Methods for preventing or treating cancer resistance to egfr inhibition | |
Joseph et al. | STING activation counters glioblastoma by vascular alteration and immune surveillance | |
Meyer et al. | An open-label, prospective phase I/II study evaluating the immunogenicity and safety of a ras peptide vaccine plus GM-CSF in patients with non-small cell lung cancer | |
WO2022247972A2 (es) | Uso de composiciones terapéuticas para el tratamiento de pacientes con tumores de origen epitelial | |
US20140056910A1 (en) | Therapeutic agent for cancer having reduced sensitivity to molecular target drug and pharmaceutical composition for enhancing sensitivity to molecular target drug | |
RU2735493C2 (ru) | Терапевтическая композиция для снижения устойчивости к ингибиторам тирозинкиназы | |
JP2023512181A (ja) | 癌を治療するためのegfr阻害剤とror1阻害剤の組み合わせ | |
TWI842966B (zh) | 一種具緩解抗癌藥物抗藥性及增加抗癌藥物敏感性之醫藥組合物及其用途 | |
WO2019012174A1 (es) | pEGFR Y FGFR1 Y/O FGFR4 PARA USO EN LA PREDICCIÓN DE LA RESPUESTA DE LOS PACIENTES A UN TRATAMIENTO DEL CÁNCER DE PULMÓN Y MÉTODO Y KIT BASADOS EN DICHO USO | |
Felsberg et al. | Prognostic role of epidermal growth factor receptor variant III (EGFRvIII) positivity in EGFR-amplified primary and recurrent glioblastomas | |
US20240156908A1 (en) | USE OF sEphB4-HSA FUSION PROTEIN AS A FIRST-LINE THERAPY IN CANCER TREATMENT | |
US9801840B1 (en) | Pharmaceutical composition and use thereof | |
Acton | Melanomas: New insights for the healthcare professional: 2013 edition | |
WO2023072043A1 (zh) | 治疗肿瘤的联用药物 | |
JP2024520477A (ja) | ペプチドに基づくネオ抗原ワクチンの多成分化学組成物 | |
WO2022115767A1 (en) | Methods of treating cancer |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
WWE | Wipo information: entry into national phase |
Ref document number: 17789888 Country of ref document: US |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 22735763 Country of ref document: EP Kind code of ref document: A2 |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2301007622 Country of ref document: TH |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2022280921 Country of ref document: AU Ref document number: 805855 Country of ref document: NZ Ref document number: AU2022280921 Country of ref document: AU |
|
WWE | Wipo information: entry into national phase |
Ref document number: 3220191 Country of ref document: CA |
|
WWE | Wipo information: entry into national phase |
Ref document number: 202280037573.4 Country of ref document: CN Ref document number: 2023573145 Country of ref document: JP Ref document number: MX/A/2023/014084 Country of ref document: MX |
|
REG | Reference to national code |
Ref country code: BR Ref legal event code: B01A Ref document number: 112023024775 Country of ref document: BR |
|
ENP | Entry into the national phase |
Ref document number: 2022280921 Country of ref document: AU Date of ref document: 20220519 Kind code of ref document: A |
|
ENP | Entry into the national phase |
Ref document number: 20237042874 Country of ref document: KR Kind code of ref document: A |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1020237042874 Country of ref document: KR |
|
WWE | Wipo information: entry into national phase |
Ref document number: 202393320 Country of ref document: EA |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2022735763 Country of ref document: EP |
|
ENP | Entry into the national phase |
Ref document number: 2022735763 Country of ref document: EP Effective date: 20240102 |
|
ENP | Entry into the national phase |
Ref document number: 112023024775 Country of ref document: BR Kind code of ref document: A2 Effective date: 20231127 |